Symbols / APVO Stock $3.90 -8.13% Aptevo Therapeutics Inc.

Healthcare • Biotechnology • United States • NCM
APVO (Stock) Chart
About

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 4.61M
Enterprise Value -12.06M Income -25.97M Sales —
Book/sh 17.42 Cash/sh 18.29 Dividend Yield —
Payout 0.00% Employees — IPO —
P/E 0.00 Forward P/E -0.21 PEG —
P/S — P/B 0.22 P/C —
EV/EBITDA 0.46 EV/Sales — Quick Ratio 3.57
Current Ratio 3.81 Debt/Eq 26.63 LT Debt/Eq —
EPS (ttm) -87.27 EPS next Y -18.65 EPS Growth —
Revenue Growth — Earnings 2025-11-06 16:00 ROA -76.87%
ROE -234.61% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 1.18M
Shs Float 1.18M Short Float 10.62% Short Ratio 1.46
Short Interest — 52W High 504.00 52W Low 3.83
Beta 1.51 Avg Volume 171.13K Volume 27.74K
Target Price $21.00 Recom Strong_buy Prev Close $4.25
Price $3.90 Change -8.13%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$21.00
Mean price target
2. Current target
$4.24
Latest analyst target
3. DCF / Fair value
$-241.90
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.24
Low
$21.00
High
$21.00
Mean
$21.00
News
RSS: Latest APVO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-10 GRANT GRADY III Director — 13,513 $1.49 $20,134
2025-07-17 HARSANYI ZSOLT Director — 1 — —
2025-07-17 TAYLOR DAPHNE L Chief Financial Officer — 3 — —
2025-07-17 WHITE MARVIN L Chief Executive Officer — 10 — —
2025-07-17 NIEDERHUBER JOHN Director — 1 — —
2025-07-17 LAMOTHE JEFFREY G Chief Operating Officer — 5 — —
2025-07-17 GRANT GRADY III Director — 1 — —
2025-07-17 KUNZ BARBARA LOPEZ Director — 1 — —
2025-07-17 ABDUN-NABI DANIEL J Director — 1 — —
2025-07-17 KWON SOYOUNG General Counsel — 3 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
3.11
Operating Revenue
0.00
0.00
0.00
-100.00%
3.11
Operating Expense
26.31
+6.95%
24.60
-14.81%
28.88
-9.06%
31.75
Research And Development
14.54
+1.13%
14.38
-15.95%
17.11
-4.33%
17.88
Selling General And Administration
11.77
+15.14%
10.22
-13.14%
11.77
-15.15%
13.87
General And Administrative Expense
11.77
+15.14%
10.22
-13.14%
11.77
-15.15%
13.87
Other Gand A
11.77
+15.14%
10.22
-13.14%
11.77
-15.15%
13.87
Total Expenses
26.31
+6.95%
24.60
-14.81%
28.88
-9.06%
31.75
Operating Income
-26.31
-6.95%
-24.60
+14.81%
-28.88
-0.83%
-28.64
Total Operating Income As Reported
-26.31
-6.95%
-24.60
+14.81%
-28.88
-0.83%
-28.64
EBITDA
-26.07
-7.51%
-24.25
+14.34%
-28.31
-2.06%
-27.74
Normalized EBITDA
-26.07
-7.51%
-24.25
+36.12%
-37.96
-36.85%
-27.74
Reconciled Depreciation
0.24
-31.82%
0.35
-37.92%
0.57
-37.07%
0.90
EBIT
-26.31
-6.95%
-24.60
+14.81%
-28.88
-0.83%
-28.64
Total Unusual Items
—
0.00
-100.00%
9.65
0.00
Total Unusual Items Excluding Goodwill
—
0.00
-100.00%
9.65
0.00
Special Income Charges
—
0.00
-100.00%
9.65
0.00
Other Special Charges
—
—
—
-37.18
Net Income
-25.97
-7.61%
-24.13
-38.59%
-17.41
-316.91%
8.03
Pretax Income
-25.97
-7.61%
-24.13
-29.38%
-18.65
-365.90%
7.01
Other Income Expense
0.34
-26.91%
0.47
-95.39%
10.23
-71.31%
35.66
Other Non Operating Income Expenses
0.34
-26.91%
0.47
-18.34%
0.58
-98.38%
35.66
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-25.97
-7.61%
-24.13
-38.59%
-17.41
-316.91%
8.03
Net Income From Continuing Operation Net Minority Interest
-25.97
-7.61%
-24.13
-29.38%
-18.65
-365.90%
7.01
Net Income From Continuing And Discontinued Operation
-25.97
-7.61%
-24.13
-38.59%
-17.41
-316.91%
8.03
Net Income Continuous Operations
-25.97
-7.61%
-24.13
-29.38%
-18.65
-365.90%
7.01
Net Income Discontinuous Operations
—
0.00
-100.00%
1.24
+22.31%
1.01
Normalized Income
-25.97
-7.61%
-24.13
+14.73%
-28.30
-503.48%
7.01
Net Income Common Stockholders
-27.54
-14.12%
-24.13
-38.59%
-17.41
-316.91%
8.03
Otherunder Preferred Stock Dividend
1.57
0.00
—
—
Diluted EPS
-87.27
+99.72%
-31,460.23
+94.04%
-527,606.06
-172.30%
729,727.27
Basic EPS
-87.27
+98.53%
-5,956.55
+98.87%
-527,606.06
-172.30%
729,727.27
Basic Average Shares
0.32
+7689.06%
0.00
+12175.76%
0.00
+200.00%
0.00
Diluted Average Shares
0.32
+7689.06%
0.00
+12175.76%
0.00
+200.00%
0.00
Diluted NI Availto Com Stockholders
-27.54
-14.12%
-24.13
-38.59%
-17.41
-316.91%
8.03
Gain On Sale Of PPE
—
0.00
-100.00%
9.65
0.00
Line Item Trend 2023-12-31
Total Assets
24.84
Current Assets
19.07
Cash Cash Equivalents And Short Term Investments
16.90
Cash And Cash Equivalents
16.90
Cash Equivalents
13.17
Cash Financial
3.73
Receivables
0.00
Other Receivables
—
Prepaid Assets
1.47
Restricted Cash
—
Other Current Assets
0.69
Total Non Current Assets
5.78
Net PPE
5.78
Gross PPE
19.37
Accumulated Depreciation
-13.59
Properties
0.00
Buildings And Improvements
4.88
Machinery Furniture Equipment
12.26
Other Properties
—
Leases
2.23
Other Non Current Assets
—
Total Liabilities Net Minority Interest
12.62
Current Liabilities
7.22
Payables And Accrued Expenses
3.98
Payables
—
Accounts Payable
—
Current Accrued Expenses
—
Pensionand Other Post Retirement Benefit Plans Current
2.10
Current Debt And Capital Lease Obligation
—
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
—
Other Current Liabilities
1.14
Total Non Current Liabilities Net Minority Interest
5.40
Long Term Debt And Capital Lease Obligation
5.40
Long Term Debt
—
Long Term Capital Lease Obligation
5.40
Other Non Current Liabilities
—
Stockholders Equity
12.22
Common Stock Equity
12.22
Capital Stock
0.06
Common Stock
0.06
Preferred Stock
0.00
Share Issued
0.00
Ordinary Shares Number
0.00
Treasury Shares Number
0.00
Additional Paid In Capital
235.61
Retained Earnings
-223.45
Total Equity Gross Minority Interest
12.22
Total Capitalization
12.22
Working Capital
11.84
Invested Capital
12.22
Total Debt
5.40
Capital Lease Obligations
5.40
Net Tangible Assets
12.22
Tangible Book Value
12.22
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-25.59
-7.60%
-23.79
-102.77%
-11.73
+44.20%
-21.02
Cash Flow From Continuing Operating Activities
-25.59
-7.60%
-23.79
-102.77%
-11.73
+44.20%
-21.02
Net Income From Continuing Operations
-25.97
-7.61%
-24.13
-38.59%
-17.41
-316.91%
8.03
Depreciation Amortization Depletion
0.24
-31.82%
0.35
-37.92%
0.57
-37.07%
0.90
Depreciation And Amortization
0.24
-31.82%
0.35
-37.92%
0.57
-37.07%
0.90
Other Non Cash Items
1.09
-1.00%
1.10
+10900.00%
0.01
+100.03%
-33.94
Stock Based Compensation
0.10
-91.02%
1.07
-51.25%
2.19
+21.70%
1.80
Operating Gains Losses
—
—
—
0.05
Gain Loss On Sale Of PPE
—
—
0.00
-100.00%
0.05
Change In Working Capital
-1.05
+51.75%
-2.18
-174.75%
2.91
+35.77%
2.14
Change In Receivables
—
0.00
-100.00%
2.50
+114.78%
1.16
Change In Prepaid Assets
0.48
+122.58%
0.22
+41.83%
0.15
-56.90%
0.35
Change In Payables And Accrued Expense
-0.16
+84.56%
-1.02
-296.33%
0.52
+231.47%
-0.39
Change In Payable
-0.16
+84.56%
-1.02
-296.33%
0.52
+231.47%
-0.39
Change In Account Payable
-0.16
+84.56%
-1.02
-296.33%
0.52
+231.47%
-0.39
Change In Other Current Assets
—
0.49
+16.59%
0.42
-35.38%
0.65
Change In Other Current Liabilities
-1.38
+0.00%
-1.38
-101.76%
-0.68
-286.34%
0.37
Investing Cash Flow
0.00
0.00
0.00
+100.00%
-0.03
Cash Flow From Continuing Investing Activities
—
—
0.00
+100.00%
-0.03
Net PPE Purchase And Sale
—
—
0.00
+100.00%
-0.03
Purchase Of PPE
—
—
0.00
+100.00%
-0.03
Capital Expenditure
—
—
—
-0.03
Net Business Purchase And Sale
—
—
—
—
Gain Loss On Sale Of Business
—
—
—
—
Financing Cash Flow
38.50
+146.85%
15.60
+160.00%
6.00
+329.28%
-2.62
Cash Flow From Continuing Financing Activities
38.50
+146.85%
15.60
+160.00%
6.00
+329.28%
-2.62
Net Issuance Payments Of Debt
—
0.00
+100.00%
-3.47
+71.74%
-12.27
Repayment Of Debt
—
0.00
+100.00%
-3.47
+71.74%
-12.27
Long Term Debt Payments
—
0.00
+100.00%
-3.47
+71.74%
-12.27
Net Long Term Debt Issuance
—
0.00
+100.00%
-3.47
+71.74%
-12.27
Net Common Stock Issuance
37.94
+278.04%
10.04
+56.13%
6.43
-7.30%
6.93
Proceeds From Stock Option Exercised
0.56
-89.99%
5.56
+82.57%
3.05
0.00
Net Other Financing Charges
—
-0.00
+60.00%
-0.01
-100.37%
2.72
Changes In Cash
12.90
+257.57%
-8.19
-42.88%
-5.73
+75.78%
-23.67
Beginning Cash Position
8.71
-48.45%
16.90
-25.32%
22.64
-51.11%
46.30
End Cash Position
21.62
+148.10%
8.71
-48.45%
16.90
-25.32%
22.64
Free Cash Flow
-25.59
-7.60%
-23.79
-102.77%
-11.73
+44.28%
-21.05
Common Stock Issuance
37.94
+278.04%
10.04
+56.13%
6.43
-7.30%
6.93
Issuance Of Capital Stock
37.94
+278.04%
10.04
+56.13%
6.43
-7.30%
6.93
Sale Of Business
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category